| 5.33 -0.06 (-1.11%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.67  |
1-year : | 8.61 |
| Resists | First : | 6.56 |
Second : | 7.38 |
| Pivot price | 6.05 |
|||
| Supports | First : | 5.25 |
Second : | 4.37 |
| MAs | MA(5) : | 5.48 |
MA(20) : | 6.21 |
| MA(100) : | 6.7 |
MA(250) : | 6.56 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 10 |
| RSI | RSI(14): 28.7 |
|||
| 52-week | High : | 10.8 | Low : | 4.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CLPT ] has closed above bottom band by 9.8%. Bollinger Bands are 23.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.53 - 5.58 | 5.58 - 5.61 |
| Low: | 5.14 - 5.21 | 5.21 - 5.25 |
| Close: | 5.25 - 5.36 | 5.36 - 5.43 |
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Fri, 19 Apr 2024
Is There Now An Opportunity In ClearPoint Neuro, Inc. (NASDAQ:CLPT)? - Yahoo Finance
Fri, 19 Apr 2024
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value? - Simply Wall St
Thu, 18 Apr 2024
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Movies Canada
Mon, 15 Apr 2024
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Short Interest Update - MarketBeat
Sat, 16 Mar 2024
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q4 2023 Earnings Call Transcript - Yahoo Finance
Fri, 15 Mar 2024
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 27 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 7.5 (%) |
| Held by Institutions | 29.1 (%) |
| Shares Short | 1,280 (K) |
| Shares Short P.Month | 1,390 (K) |
| EPS | -0.9 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.86 |
| Profit Margin | -92.3 % |
| Operating Margin | -69.1 % |
| Return on Assets (ttm) | -28.6 % |
| Return on Equity (ttm) | -76.1 % |
| Qtrly Rev. Growth | 31.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.88 |
| EBITDA (p.s.) | -0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -5.93 |
| PEG Ratio | -0.3 |
| Price to Book value | 6.19 |
| Price to Sales | 6.02 |
| Price to Cash Flow | -10.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|